Astronics (ATRO) 10-Q 15 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Oct. 01, 2022	Nov. 07, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Oct. 01, 2022
Document Transition Report	false
Entity File Number	0-7087
Entity Registrant Name	ASTRONICS CORPORATION
Entity Incorporation, State or Country Code	NY
Entity Tax Identification Number	16-0959303
Entity Address, Address Line One	130 Commerce Way
Entity Address, City or Town	East Aurora
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	14052
City Area Code	716
Local Phone Number	805-1599
Title of 12(b) Security	Common Stock, $.01 par value per share
Trading Symbol	ATRO
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		32,171,112
Entity Central Index Key	0000008063
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Amendment Flag	false

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Current Assets:
Cash and Cash Equivalents	$ 2,568	$ 29,757
Accounts Receivable, Net of Allowance for Estimated Credit Losses	133,835	107,439
Inventories	190,198	157,576
Prepaid Expenses and Other Current Assets	20,736	45,089
Total Current Assets	347,337	339,861
Property, Plant and Equipment, Net of Accumulated Depreciation	90,640	95,236
Operating Right-of-Use Assets	14,463	16,169
Other Assets	5,490	5,270
Intangible Assets, Net of Accumulated Amortization	82,814	94,320
Goodwill	58,143	58,282
Total Assets	598,887	609,138
Current Liabilities:
Accounts Payable	53,216	34,860
Current Operating Lease Liabilities	4,971	6,778
Accrued Expenses and Other Current Liabilities	46,253	49,619
Customer Advance Payments and Deferred Revenue	29,048	27,356
Total Current Liabilities	133,488	118,613
Long-term Debt	159,000	163,000
Long-term Operating Lease Liabilities	10,966	12,018
Other Liabilities	58,345	58,903
Total Liabilities	361,799	352,534
Shareholders’ Equity:
Common Stock	354	353
Accumulated Other Comprehensive Loss	(16,690)	(14,495)
Other Shareholders’ Equity	253,424	270,746
Total Shareholders’ Equity	237,088	256,604
Total Liabilities and Shareholders’ Equity	$ 598,887	$ 609,138

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Income Statement [Abstract]
Sales	$ 131,438	$ 111,841	$ 376,741	$ 328,856
Cost of Products Sold	117,050	94,610	326,711	281,957
Gross Profit	14,388	17,231	50,030	46,899
Selling, General and Administrative Expenses	28,702	21,729	76,907	66,829
Loss from Operations	(14,314)	(4,498)	(26,877)	(19,930)
Net Gain on Sale of Business	0	0	(11,284)	0
Other Expense, Net of Other Income	427	546	1,180	1,627
Interest Expense, Net of Interest Income	2,519	1,795	5,812	5,252
Loss Before Income Taxes	(17,260)	(6,839)	(22,585)	(26,809)
Provision for (Benefit from) Income Taxes	(2,403)	335	6,383	373
Net Loss	$ (14,857)	$ (7,174)	$ (28,968)	$ (27,182)
Loss Per Share:
Basic (in usd per share)	$ (0.46)	$ (0.23)	$ (0.90)	$ (0.88)
Diluted (in usd per share)	$ (0.46)	$ (0.23)	$ (0.90)	$ (0.88)

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Statement of Comprehensive Income [Abstract]
Net Loss	$ (14,857)	$ (7,174)	$ (28,968)	$ (27,182)
Other Comprehensive (Loss) Income:
Foreign Currency Translation Adjustments	(1,674)	(1,143)	(3,241)	(1,165)
Retirement Liability Adjustment – Net of Tax	348	434	1,046	1,302
Total Other Comprehensive (Loss) Income	(1,326)	(709)	(2,195)	137
Comprehensive Loss	$ (16,183)	$ (7,883)	$ (31,163)	$ (27,045)

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021
Cash Flows from Operating Activities:
Net Loss	$ (28,968)	$ (27,182)
Adjustments to Reconcile Net Loss to Cash Flows from Operating Activities:
Depreciation and Amortization	20,905	21,950
Provisions for Non-Cash Losses on Inventory and Receivables	1,033	2,750
Equity-based Compensation Expense	5,178	5,147
Non-Cash Accrued 401K Contribution	3,300	0
Deferred Tax Benefit	0	(145)
Non-Cash Severance Expense	0	182
Operating Lease Non-Cash Expense	4,568	3,783
Non-cash Litigation Provision	2,000	0
Net Gain on Sale of Business, Before Taxes	(11,284)	0
Contingent Consideration Liability Fair Value Adjustment	0	(2,200)
Other	2,997	3,010
Cash Flows from Changes in Operating Assets and Liabilities:
Accounts Receivable	(28,196)	(15,027)
Inventories	(35,444)	(3,255)
Accounts Payable	17,595	(1,883)
Accrued Expenses	638	1,733
Other Current Assets and Liabilities	(4,015)	(666)
Customer Advance Payments and Deferred Revenue	1,990	(2,215)
Income Taxes	14,583	217
Operating Lease Liabilities	(5,715)	(4,395)
Supplemental Retirement Plan and Other Liabilities	(306)	(304)
Cash Flows from Operating Activities	(39,141)	(18,500)
Cash Flows from Investing Activities:
Proceeds from Sale of Business and Assets	21,981	30
Capital Expenditures	(4,283)	(4,639)
Cash Flows from Investing Activities	17,698	(4,609)
Cash Flows from Financing Activities:
Proceeds from Long-term Debt	109,625	20,000
Principal Payments on Long-term Debt	(113,625)	(10,000)
Stock Award Activity	104	3,187
Finance Lease Principal Payments	(85)	(878)
Debt Acquisition Costs	(968)	0
Cash Flows from Financing Activities	(4,949)	12,309
Effect of Exchange Rates on Cash	(797)	(521)
Decrease in Cash and Cash Equivalents	(27,189)	(11,321)
Cash and Cash Equivalents at Beginning of Period	29,757	40,412
Cash and Cash Equivalents at End of Period	2,568	29,091
Non-Cash Investing Activities:
Capital Expenditures in Accounts Payable	$ 1,392	$ 0

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock Common Stock	Common Stock Convertible Class B Stock	Additional Paid in Capital	Accumulated Comprehensive Loss	Retained Earnings	Treasury Stock
Beginning of Period at Dec. 31, 2020		$ 278	$ 69	$ 82,187	$ (16,450)	$ 312,803	$ (108,516)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Issuance of Common Stock for Restricted Stock Units (“RSU’s”)		6
Class B Stock Converted to Common Stock		5	(5)
Net Exercise of Stock Options and Equity-based Compensation Expense				8,328
Foreign Currency Translation Adjustments	$ (1,165)				(1,165)
Retirement Liability Adjustment – Net of Taxes					1,302
Net Loss	(27,182)					(27,182)
End of Period at Oct. 02, 2021	251,660	$ 289	$ 64	90,515	(16,313)	285,621	$ (108,516)
Beginning of Period (in shares) at Dec. 31, 2020		27,825,000	6,877,000				3,808,000
Increase (Decrease) in Stockholders' Equity (in shares)
Net Issuance from Exercise of Stock Options (in shares)		554,000	13,000
Class B Stock Converted to Common Stock (in shares)		512,000	(512,000)
End of Period (in shares) at Oct. 02, 2021		28,891,000	6,378,000				3,808,000
Beginning of Period at Jul. 03, 2021		$ 283	$ 64	85,829	(15,604)	292,795	$ (108,516)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Issuance of Common Stock for Restricted Stock Units (“RSU’s”)		6
Net Exercise of Stock Options and Equity-based Compensation Expense				4,686
Foreign Currency Translation Adjustments	(1,143)				(1,143)
Retirement Liability Adjustment – Net of Taxes					434
Net Loss	(7,174)					(7,174)
End of Period at Oct. 02, 2021	251,660	$ 289	$ 64	90,515	(16,313)	285,621	$ (108,516)
Beginning of Period (in shares) at Jul. 03, 2021		28,315,000	6,420,000				3,808,000
Increase (Decrease) in Stockholders' Equity (in shares)
Net Issuance from Exercise of Stock Options (in shares)		534,000
Class B Stock Converted to Common Stock (in shares)		42,000	(42,000)
End of Period (in shares) at Oct. 02, 2021		28,891,000	6,378,000				3,808,000
Beginning of Period at Dec. 31, 2021	256,604	$ 289	$ 64	92,037	(14,495)	287,225	$ (108,516)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Issuance of Common Stock for Restricted Stock Units (“RSU’s”)		1
Class B Stock Converted to Common Stock		1	(1)
Net Exercise of Stock Options and Equity-based Compensation Expense				5,579
Tax Withholding Related to Issuance of RSU’s				(298)
Foreign Currency Translation Adjustments	(3,241)				(3,241)
Retirement Liability Adjustment – Net of Taxes					1,046
Net Loss	(28,968)					(28,968)
Shares Issued to Fund 401K Obligation						(9,158)	15,523
End of Period at Oct. 01, 2022	237,088	$ 291	$ 63	97,318	(16,690)	249,099	$ (92,993)
Beginning of Period (in shares) at Dec. 31, 2021		28,911,000	6,375,000				3,808,000
Increase (Decrease) in Stockholders' Equity (in shares)
Net Issuance from Exercise of Stock Options (in shares)		20,000	24,000
Net Issuance of Common Stock for RSU’s (in shares)		105,000
Class B Stock Converted to Common Stock (in shares)		74,000	(74,000)
Shares issued to fund 401k obligation (in shares)							(545,000)
End of Period (in shares) at Oct. 01, 2022		29,110,000	6,325,000				3,263,000
Beginning of Period at Jul. 02, 2022		$ 290	$ 64	95,861	(15,364)	266,338	$ (96,513)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Class B Stock Converted to Common Stock		1	(1)
Net Exercise of Stock Options and Equity-based Compensation Expense				1,457
Foreign Currency Translation Adjustments	(1,674)				(1,674)
Retirement Liability Adjustment – Net of Taxes					348
Net Loss	(14,857)					(14,857)
Shares Issued to Fund 401K Obligation						(2,382)	3,520
End of Period at Oct. 01, 2022	$ 237,088	$ 291	$ 63	$ 97,318	$ (16,690)	$ 249,099	$ (92,993)
Beginning of Period (in shares) at Jul. 02, 2022		29,047,000	6,331,000				3,387,000
Increase (Decrease) in Stockholders' Equity (in shares)
Net Issuance of Common Stock for RSU’s (in shares)		57,000
Class B Stock Converted to Common Stock (in shares)		6,000	(6,000)
Shares issued to fund 401k obligation (in shares)							(124,000)
End of Period (in shares) at Oct. 01, 2022		29,110,000	6,325,000				3,263,000

Basis of Presentation

Basis of Presentation	9 Months Ended
	Oct. 01, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included. Operating Results The results of operations for any interim period are not necessarily indicative of results for the full year. In addition, the COVID-19 pandemic and supply chain disruptions have increased the volatility we experience in our financial results in recent periods and this could continue in future interim and annual periods. Operating results for the nine months ended October 1, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The balance sheet at December 31, 2021 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements. For further information, refer to the financial statements and footnotes thereto included in Astronics Corporation’s 2021 annual report on Form 10-K. Description of the Business Astronics Corporation (“Astronics” or the “Company”) is a leading provider of advanced technologies to the global aerospace, defense and electronics industries. Our products and services include advanced, high-performance electrical power generation, distribution and motion systems, lighting and safety systems, avionics products, systems and certification, aircraft structures and automated test systems. We have principal operations in the United States (“U.S.”), Canada, France and England, as well as engineering offices in the Ukraine and India. On February 13, 2019, the Company completed a divestiture of its semiconductor test business within the Test Systems segment. The transaction included two elements of contingent earnouts. In December 2021, the Company agreed to a payment of $10.7 million for the calendar 2020 earnout, which was recorded in the fourth quarter of 2021 and was received by the Company in early January 2022. In March 2022, the Company agreed with the earnout calculation for the calendar 2021 earnout in the amount of $11.3 million. The Company recorded the gain and received the payment in the first quarter of 2022. Impact of the COVID-19 Pandemic On March 11, 2020, the World Health Organization classified the COVID-19 outbreak as a pandemic. The spread of the COVID-19 pandemic disrupted businesses on a global scale, led to significant volatility in financial markets and affected the aviation and industrial industries. Substantially all of our operations and production activities have, to-date, remained operational. However, the impacts of the pandemic have placed labor and supply chain pressures on our business and we have been impacted by customer demand variability. Although we saw stable and growing backlog during the first three quarters of 2022 in our aerospace business, COVID-19 related disruptions are ongoing and continue to adversely challenge our commercial transport market. While we remain bullish about the aerospace business, we believe the recovery to pre-pandemic activity, particularly in the widebody market, will take longer than originally anticipated at the outset of the pandemic. As economic activity continues to recover, we will continue to monitor the situation, assessing further possible implications on our operations, supply chain, liquidity, cash flow and customer orders. The Company qualified for government subsidies from the Canadian and French governments as a result of the COVID-19 pandemic’s impact on our foreign operations. The Canadian and French subsidies are income-based grants intended to reimburse the Company for certain employee wages. The grants are recognized as income over the periods in which the Company recognizes as expenses the costs the grants are intended to defray. The amount recognized during the three and nine months ended October 1, 2022 was immaterial. In September 2021 the Company was awarded a grant of up to $14.7 million from the U.S. Department of Transportation (“USDOT”) under the Aviation Manufacturing Jobs Protection Program (“AMJP”). The Company received $7.4 million under the grant in 2021, $5.2 million in the first quarter of 2022 and $2.1 million in the third quarter of 2022. The grant benefit was recognized ratably over the six-month performance period as a reduction to cost of products sold in proportion to the compensation expense that the award is intended to defray. During the nine months ended October 1, 2022, the Company recognized $6.0 million of the award. The following table presents the COVID-19 related government assistance, including AMJP, recorded during the three and nine months ended October 1, 2022 and October 2, 2021: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Reduction in Cost of Products Sold $ 6,008 $ 3,185 $ — $ 1,706 Reduction in Selling, General and Administrative Expenses — 190 — 43 Total $ 6,008 $ 3,375 $ — $ 1,749 Trade Accounts Receivable and Contract Assets The allowance for estimated credit losses is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as the age of the receivable balances, historical experience, credit quality, current economic conditions, and reasonable and supportable forecasts of future economic conditions that may affect a customer’s ability to pay. The allowance for estimated credit losses balance was $3.4 million and $3.2 million at October 1, 2022 and December 31, 2021, respectively. The Company’s bad debt expense was $0.3 million and $0.4 million during the three and nine months ended October 1, 2022 and insignificant during the three and nine months ended October 2, 2021. Total write-offs charged against the allowance were insignificant in both the three and nine months ended October 1, 2022 and October 2, 2021. Total recoveries were insignificant in both the three and nine months ended October 1, 2022 and October 2, 2021. The Company's exposure to credit losses may increase if its customers are adversely affected by global economic recessions, disruption associated with the current COVID-19 pandemic, industry conditions, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables and contract assets as airlines and other aerospace companies’ cash flows are impacted by the COVID-19 pandemic. Research and Development Expenses Research and development costs are expensed as incurred and include salaries, benefits, consulting, material costs and depreciation. Research and development expenses amounted to $12.0 million and $11.3 million for the three months ended and $36.8 million and $31.9 million for the nine months ended October 1, 2022 and October 2, 2021, respectively. These costs are included in cost of products sold. Goodwill Impairment The Company tests goodwill at the reporting unit level on an annual basis or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. As of October 1, 2022, the Company concluded that no indicators of impairment relating to intangible assets or goodwill existed and an interim test was not performed in the three or nine months then ended. Valuation of Long-Lived Assets Long-lived assets are evaluated for recoverability whenever adverse effects or changes in circumstances indicate that the carrying value may not be recoverable. The recoverability test consists of comparing the undiscounted projected cash flows with the carrying amount. Should the carrying amount exceed undiscounted projected cash flows, an impairment loss would be recognized to the extent the carrying amount exceeds fair value. As of October 1, 2022 and for the three and nine month periods then ended, the Company concluded that no indicators of impairment relating to long-lived assets existed. Foreign Currency Translation The aggregate foreign currency transaction gain or loss included in operations was insignificant for the three and nine months ended October 1, 2022 and October 2, 2021. Newly Adopted Accounting Pronouncement Recent Accounting Pronouncement Adopted Standard Description Financial Statement Effect or Other Significant Matters ASU No. 2021-08 Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers This amendment requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Topic 606, Revenue from Contracts with Customers , as if it had originated the contracts. Under the current business combinations guidance, such assets and liabilities are recognized by the acquirer at fair value on the acquisition date. The standard will not impact acquired contract assets or liabilities from business combinations occurring prior to the adoption date. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The impact of adoption on the Company's consolidated financial statements will be prospective only and depend on the magnitude of future business acquisitions. Date of adoption: Q1 2022 We consider the applicability and impact of all ASUs. ASUs not listed above were assessed and determined to be either not applicable, or had or are expected to have minimal impact on our financial statements and related disclosures.

Revenue

Revenue	9 Months Ended
	Oct. 01, 2022
Revenue from Contract with Customer [Abstract]
Revenue	Revenue On October 1, 2022, we had $547.1 million of remaining performance obligations, which we refer to as total backlog. We expect to recognize approximately $426.5 million of our remaining performance obligations as revenue over the next twelve months and the balance thereafter. We recognized $7.3 million and $6.5 million during the three months ended and $13.3 million and $15.1 million during the nine months ended October 1, 2022 and October 2, 2021, respectively, in revenues that were included in the contract liability balance at the beginning of the period. The Company's contract assets and contract liabilities consist primarily of costs and profits in excess of billings and billings in excess of cost and profits, respectively. The following table presents the beginning and ending balances of contract assets and contract liabilities during the nine months ended October 1, 2022: (In thousands) Contract Assets Contract Liabilities Beginning Balance, January 1, 2022 $ 25,941 $ 28,495 Ending Balance, October 1, 2022 $ 31,263 $ 29,838 The Company recognizes an asset for certain, material costs to fulfill a contract if it is determined that the costs relate directly to a contract or an anticipated contract that can be specifically identified, generate or enhance resources that will be used in satisfying performance obligations in the future, and are expected to be recovered. Such costs are amortized on a systematic basis that is consistent with the transfer to the customer of the goods to which the asset relates. Start-up costs are expensed as incurred. Capitalized fulfillment costs are included in Inventories in the accompanying Consolidated Balance Sheets. Should future orders not materialize or it is determined the costs are no longer probable of recovery, the capitalized costs are written off. As of October 1, 2022, the Company has capitalized $1.6 million of costs. As of December 31, 2021, the Company did not have material capitalized fulfillment costs. The following table presents our revenue disaggregated by Market Segments as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Aerospace Segment Commercial Transport $ 211,721 $ 143,550 $ 78,389 $ 57,549 Military 41,336 54,847 12,463 17,064 General Aviation 48,748 41,131 14,751 12,109 Other 21,056 26,874 6,574 9,044 Aerospace Total 322,861 266,402 112,177 95,766 Test Systems Segment Aerospace & Defense 53,880 62,454 19,261 16,075 Test Systems Total 53,880 62,454 19,261 16,075 Total $ 376,741 $ 328,856 $ 131,438 $ 111,841 The following table presents our revenue disaggregated by Product Lines as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Aerospace Segment Electrical Power & Motion $ 132,757 $ 102,742 $ 46,155 $ 38,650 Lighting & Safety 90,339 76,929 29,740 25,461 Avionics 67,453 47,355 24,172 14,491 Systems Certification 6,656 7,937 3,985 6,099 Structures 4,600 4,565 1,551 2,021 Other 21,056 26,874 6,574 9,044 Aerospace Total 322,861 266,402 112,177 95,766 Test Systems 53,880 62,454 19,261 16,075 Total $ 376,741 $ 328,856 $ 131,438 $ 111,841

Inventories

Inventories	9 Months Ended
	Oct. 01, 2022
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories consisted of the following: ( In thousands ) October 1, 2022 December 31, 2021 Finished Goods $ 32,484 $ 28,579 Work in Progress 33,867 22,954 Raw Material 123,847 106,043 $ 190,198 $ 157,576 The Company has evaluated the carrying value of existing inventories and believe they are properly reflected at their lower of carrying value or net realizable value. Future changes in demand or other market developments could result in future inventory charges. The Company is actively managing inventories and aligning them to meet known current and future demand.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Oct. 01, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, Plant and Equipment Property, Plant and Equipment consisted of the following: (In thousands) October 1, 2022 December 31, 2021 Land $ 8,501 $ 8,632 Buildings and Improvements 69,986 70,566 Machinery and Equipment 122,337 121,960 Construction in Progress 8,384 5,680 209,208 206,838 Less Accumulated Depreciation 118,568 111,602 $ 90,640 $ 95,236

Intangible Assets

Intangible Assets	9 Months Ended
	Oct. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets The following table summarizes acquired intangible assets as follows: October 1, 2022 December 31, 2021 (In thousands) Weighted Average Life Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Patents 11 years $ 2,146 $ 2,044 $ 2,146 $ 1,979 Non-compete Agreement 4 years 11,082 10,972 11,082 10,592 Trade Names 10 years 11,339 9,151 11,447 8,518 Completed and Unpatented Technology 9 years 47,747 33,784 47,932 30,441 Customer Relationships 15 years 141,939 75,488 142,276 69,033 Total Intangible Assets 12 years $ 214,253 $ 131,439 $ 214,883 $ 120,563 All acquired intangible assets other than goodwill and one trade name are being amortized. Amortization expense for acquired intangibles is summarized as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Amortization Expense $ 11,254 $ 11,565 $ 3,728 $ 3,853 Amortization expense for acquired intangible assets expected for 2022 and for each of the next five years is summarized as follows: (In thousands) 2022 $ 14,922 2023 $ 13,878 2024 $ 12,856 2025 $ 10,935 2026 $ 9,533 2027 $ 7,825

Goodwill

Goodwill	9 Months Ended
	Oct. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The following table summarizes the changes in the carrying amount of goodwill for the nine months ended October 1, 2022: (In thousands) December 31, 2021 Foreign Currency Translation October 1, 2022 Aerospace $ 36,648 $ (140) $ 36,508 Test Systems 21,634 1 21,635 $ 58,282 $ (139) $ 58,143 The Company tests goodwill at the reporting unit level on an annual basis or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. As of October 1, 2022 and October 2, 2021, the Company concluded that no indicators of impairment relating to intangible assets or goodwill existed and an interim test was not performed in the three or nine months then ended.

Long-Term Debt and Notes Payabl

Long-Term Debt and Notes Payable	9 Months Ended
	Oct. 01, 2022
Debt Disclosure [Abstract]
Long-term Debt and Notes Payable	Long-term Debt and Notes Payable The Company's long-term debt consists of borrowings under its Fifth Amended and Restated Credit Agreement (the “Agreement”). On March 1, 2022, the Company executed an amendment to the Agreement, which reduced the revolving credit line from $375 million to $225 million and extended the maturity date of the loans under the facility from February 16, 2023 to May 30, 2023. The definition of Adjusted EBITDA was modified to exclude income from earnout payments and asset sales. On August 9, 2022, the Company executed a further amendment to the Agreement, which reduced the revolving credit line from $225 million to $190 million until September 12, 2022 with further reductions to $180 million effective September 12, 2022 and $170 million effective October 11, 2022. The amendment extended the maturity date of the loans under the facility from May 30, 2023 to August 31, 2023. On October 21, 2022, the Company executed an additional amendment to the Agreement, under which the lenders waived enforcement of their rights against the Company arising from the Company’s failure to comply with the maximum net leverage ratio and minimum liquidity covenants, each as of September 30, 2022. The amendment increased the revolving credit line to $180 million as of October 21, 2022, with a reduction to $170 million effective November 21, 2022. Under the provisions of this amendment, the inclusion of any “going concern” language in the Company’s financial statements would constitute an event of default. A further amendment to the Agreement was executed on November 14, 2022 (the “Amended Facility”), which extended the maturity date of the loans under the facility from August 31, 2023 to November 30, 2023. Under the Amended Facility, the revolving credit line is set at $180 million, with a reduction to $170 million effective December 21, 2022. The amendment requires the Company to maintain minimum liquidity, defined as unrestricted cash plus the unused revolving credit commitments, of $10 million as of November 30, 2022 and December 31, 2022, and $15 million at the end of any month thereafter. The Amended Facility requires the Company to comply with a minimum Adjusted EBITDA covenant on a trailing twelve month basis, set at $15 million as of December 31, 2022 and March 31, 2023, and $25 million in each quarter thereafter. The amendment eliminated the net leverage ratio covenant for the remaining term of the agreement. At October 1, 2022, there was $159.0 million outstanding on the revolving credit facility and there remained $19.9 million available subject to the minimum liquidity covenant discussed above, net of outstanding letters of credit. The credit facility allocates up to $20 million of the $180 million revolving credit line for the issuance of letters of credit, including certain existing letters of credit. At October 1, 2022, outstanding letters of credit totaled $1.1 million. Interest is payable on the unpaid principal amount of the facility at a rate equal to the Secured Overnight Financing Rate (“SOFR”, which shall be at least 1.00%), plus 5.50%. Effective January 17, 2023, interest is payable on the unpaid principal amount of the facility at a rate equal to SOFR (which shall be at least 1.00%), plus 8.50%. The Company also pays a commitment fee to the lenders in an amount equal to 0.40% on the undrawn portion of the Amended Facility. Each amendment executed in 2022 required payment of a consent fee of 5 to 10 basis points of the commitment for each consenting lender. The Amended Facility restricts dividend payments and share repurchases through the maturity date of the Amended Facility. The Company’s obligations under the Amended Facility are jointly and severally guaranteed by each domestic subsidiary of the Company other than non-material subsidiaries. The obligations are secured by a first priority lien on substantially all of the Company’s and the guarantors’ assets. In the event of voluntary or involuntary bankruptcy of the Company or any subsidiary, all unpaid principal and other amounts owing under the Amended Facility automatically become due and payable. Other events of default, such as failure to make payments as they become due and breach of financial and other covenants, change of control, judgments over a certain amount, and cross default under other agreements give the agent the option to declare all such amounts immediately due and payable. We are currently in the process of evaluating terms and conditions for a new long-term financing arrangement, which includes an asset-based lending agreement and separate term loan agreement, and expect to complete the process in the coming weeks. The extent to which we will be able to effect such refinancing, replacement or maturity extension on terms that are favorable to us or at all is dependent on a number of uncertain factors, including then-prevailing credit and other market conditions, economic conditions, particularly in the aerospace and defense markets, disruptions or volatility caused by factors such as COVID-19, regional conflicts, inflation, and supply chain disruptions. In addition, rising interest rates could limit our ability to refinance our existing credit facility when it matures or cause us to pay higher interest rates upon refinancing. As the Company’s long-term debt approaches maturity, if the Company is unable to refinance, replace or extend the maturity on its credit facility, the Company’s liquidity, results of operations, and financial condition could be materially adversely impacted. If we are unable to obtain a new long-term financing facility before we file our 2022 Form 10-K to replace our existing debt facility, borrowings outstanding under our existing credit facility will come due within 12 months of that filing date and could result in substantial doubt about our ability to continue as a going concern in the event that we are not reasonably assured to have sufficient cash balances to repay the remaining obligations at maturity. The Company expects its sales growth and improvement in inventory management will provide sufficient cash flows to fund operations. However, the Company may also evaluate various actions and alternatives to enhance its cash generation from operating activities, which could include manufacturing efficiency initiatives, working with vendors and suppliers to reduce lead times and expedite shipment of critical components, and working with customers to expedite receivable collections.

Product Warranties

Product Warranties	9 Months Ended
	Oct. 01, 2022
Guarantees [Abstract]
Product Warranties	Product Warranties In the ordinary course of business, the Company warrants its products against defects in design, materials and workmanship typically over periods ranging from twelve Activity in the warranty accrual is summarized as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Balance at Beginning of Period $ 8,183 $ 7,018 $ 7,759 $ 6,835 Warranties Issued 2,541 3,506 858 1,485 Warranties Settled (2,769) (2,427) (859) (764) Reassessed Warranty Exposure (221) (808) (24) (267) Balance at End of Period $ 7,734 $ 7,289 $ 7,734 $ 7,289

Income Taxes

Income Taxes	9 Months Ended
	Oct. 01, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The effective tax rates were approximately 13.9% and (4.9)% for the three months ended and (28.3)% and (1.4)% for the nine months ended October 1, 2022 and October 2, 2021, respectively. Beginning with the 2022 tax year, certain research and development costs are required to be capitalized and amortized over sixty months for income tax purposes. The tax rate in the 2022 period was impacted by a valuation allowance applied against the deferred tax asset associated with the research and development costs that are expected to be capitalized and was partially offset by the removal of valuation allowances related to net operating losses, tax credit carryovers, and certain timing differences that are expected to reverse during 2022. In addition, the tax rate in the 2022 period was also impacted by state income taxes and the federal research and development credit expected for 2022. The Company records a valuation allowance against the deferred tax assets if and to the extent it is more likely than not that the Company will not recover the deferred tax assets. In evaluating the need for a valuation allowance, the Company weighs all relevant positive and negative evidence, and considers among other factors, historical financial performance, projected future taxable income, scheduled reversals of deferred tax liabilities, the overall business environment, and tax planning strategies. Losses in recent periods and cumulative pre-tax losses in the three year period ending with the current year, combined with the significant uncertainty brought about by the COVID-19 pandemic, is collectively considered significant negative evidence under ASC 740 when assessing whether an entity can use projected income as a basis for concluding that deferred tax assets are realizable on a more-likely than not basis. For purposes of assessing the recoverability of deferred tax assets, the Company determined that it could not include future projected earnings in the analysis due to recent history of losses and therefore had insufficient objective positive evidence that the Company will generate sufficient future taxable income to overcome the negative evidence of cumulative losses. Accordingly, during the years ended December 31, 2021 and 2020, the Company determined that a portion of its deferred tax assets are not expected to be realizable in the future and the Company continues to maintain the valuation allowance against its deferred tax assets as of October 1, 2022.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Oct. 01, 2022
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic and diluted weighted-average shares outstanding are as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Weighted Average Shares - Basic 32,085 30,927 32,241 30,954 Net Effect of Dilutive Stock Options — — — — Weighted Average Shares - Diluted 32,085 30,927 32,241 30,954 Stock options with exercise prices greater than the average market price of the underlying common shares are excluded from the computation of diluted earnings per share because they are out-of-the-money and the effect of their inclusion would be anti-dilutive. The number of common shares covered by out-of-the-money stock options was approximately 1,106,000 shares as of October 1, 2022 and 647,000 shares as of October 2, 2021. Further, due to our net loss in the three and nine month periods ended October 1, 2022 and October 2, 2021, the assumed exercise of stock compensation had an antidilutive effect and therefore was excluded from the computation of diluted loss per share. Currently, the Company expects to fund the 401K contribution for the quarter ended October 1, 2022 with treasury stock in lieu of cash. The earnings per share calculation for the quarter ended October 1, 2022 is inclusive of the approximately 0.1 million in shares outstanding for the equivalent shares needed to fulfill the obligation using the closing share price as of October 1, 2022. Actual shares issued may differ based on the sale price on the settlement date.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Oct. 01, 2022
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity Share Buyback and Reissuance The Company’s Board of Directors from time to time authorizes the repurchase of common stock, which allows the Company to purchase shares of its common stock in accordance with applicable securities laws on the open market or through privately negotiated transactions. Common shares repurchased by the Company are recorded at cost as treasury shares and result in a reduction of equity. Under its current credit agreement, and as described further in Note 7, the Company is currently restricted from further stock repurchases. When treasury shares are reissued, the Company determines the cost using an average cost method. The difference between the average cost of the treasury shares and reissuance price is included in Additional paid-in capital or Retained earnings. During the nine months ended October 1, 2022, the Company reissued 545,000 treasury shares and recorded the difference between the average cost and the reissuance price, $9.2 million, as a reduction to Retained earnings. Comprehensive Loss and Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss are as follows: (In thousands) October 1, 2022 December 31, 2021 Foreign Currency Translation Adjustments $ (8,648) $ (5,407) Retirement Liability Adjustment – Before Tax (10,324) (11,370) Tax Benefit of Retirement Liability Adjustment 2,282 2,282 Retirement Liability Adjustment – After Tax (8,042) (9,088) Accumulated Other Comprehensive Loss $ (16,690) $ (14,495) The components of other comprehensive (loss) income are as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Foreign Currency Translation Adjustments $ (3,241) $ (1,165) $ (1,674) $ (1,143) Retirement Liability Adjustments: Reclassifications to General and Administrative Expense: Amortization of Prior Service Cost 302 302 101 101 Amortization of Net Actuarial Losses 744 1,000 247 333 Retirement Liability Adjustment 1,046 1,302 348 434 Other Comprehensive (Loss) Income $ (2,195) $ 137 $ (1,326) $ (709)

Supplemental Retirement Plan an

Supplemental Retirement Plan and Related Post Retirement Benefits	9 Months Ended
	Oct. 01, 2022
Retirement Benefits [Abstract]
Supplemental Retirement Plan and Related Post Retirement Benefits	Supplemental Retirement Plan and Related Post Retirement Benefits The Company has two non-qualified supplemental retirement defined benefit plans (“SERP” and “SERP II”) for certain current and retired executive officers. The following table sets forth information regarding the net periodic pension cost for the plans. Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Service Cost $ 103 $ 146 $ 34 $ 49 Interest Cost 626 573 209 192 Amortization of Prior Service Cost 290 290 97 97 Amortization of Net Actuarial Losses 712 970 238 324 Net Periodic Cost $ 1,731 $ 1,979 $ 578 $ 662 Participants in the SERP are entitled to paid medical, dental and long-term care insurance benefits upon retirement under the plan. The Company also has a defined benefit plan related to its subsidiary in France. The net periodic cost for both plans for the three and nine months ended October 1, 2022 and October 2, 2021 is immaterial. The service cost component of net periodic benefit costs above is recorded in Selling, General and Administrative Expenses within the Consolidated Condensed Statements of Operations, while the remaining components are recorded in Other Expense, Net of Other Income.

Sales to Major Customers

Sales to Major Customers	9 Months Ended
	Oct. 01, 2022
Risks and Uncertainties [Abstract]
Sales to Major Customers	Sales to Major CustomersThe loss of major customers or a significant reduction in business with a major customer would significantly, negatively impact our sales and earnings. In the three and nine months ended October 1, 2022 and October 2, 2021, the Company had no customers in excess of 10% of consolidated sales.

Legal Proceedings

Legal Proceedings	9 Months Ended
	Oct. 01, 2022
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	Legal Proceedings Lufthansa One of the Company’s subsidiaries is involved in numerous patent infringement actions brought by Lufthansa Technik AG (“Lufthansa”) in Germany, UK and France. The Company is vigorously defending all such litigation and proceedings. Additional information about these legal proceedings can be found in Note 19 “Legal Proceedings” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. As previously disclosed, under English law, Lufthansa has the option of pursuing a claim in the UK matter in relation to the defendants’ profits from their infringing activities or pursuing a claim in relation to Lufthansa’s own lost profits. In September 2022, Lufthansa elected to claim damages based on defendants’ profits. The reserve for the German indirect claim and UK damages and interest was approximately $24.6 million at December 31, 2021 and $24.1 million at October 1, 2022, which included an additional $0.1 million and $0.5 million in interest accrued during the three and nine months ended October 1, 2022. The Company currently believes it is unlikely that the appeals process will be completed or the damages and related interest will be paid within the next twelve months. Therefore, the liability related to these matters is classified within Other Liabilities (non-current) in the Consolidated Condensed Balance Sheets at October 1, 2022 and December 31, 2021. There were no other significant developments in any of these matters during the three and nine months ended October 1, 2022. At December 31, 2021, we had recorded a liability of $1.0 million for reimbursement of Lufthansa’s legal expenses associated with the UK matter. During the nine months ended October 1, 2022, $0.3 million was paid. The remaining liability of $0.7 million is expected to be paid within the next twelve months and, as such, is classified in Accrued Expenses and Other Current Liabilities in the accompanying Consolidated Condensed Balance Sheet as of October 1, 2022. Other On March 23, 2020, Teradyne, Inc. filed a complaint against the Company and its subsidiary, Astronics Test Systems (“ATS”) (together, “the Defendants”) in the United States District Court for the Central District of California alleging patent and copyright infringement, and certain other related claims. The Defendants moved to dismiss certain claims from the case. On November 6, 2020, the Court dismissed the Company from the case, and also dismissed a number of claims, though the patent and copyright infringement claims remain. The case proceeded to discovery. In addition, on December 21, 2020, ATS filed a petition for inter partes review (“IPR”) with the US Patent Trial and Appeal Board (“PTAB”), seeking to invalidate the subject patent, and on July 21, 2021, the PTAB instituted IPR. ATS requested and, on August 26, 2021, the District Court granted, a stay of litigation during the IPR proceeding. Oral arguments on the IPR were held on April 21, 2022. The PTAB issued its decision on July 20, 2022, in which it invalidated all of Teradyne’s patent claims. The stay of litigation was lifted with respect to the remaining claims in August 2022 and discovery has resumed. No amounts have been accrued for this matter in the October 1, 2022 or December 31, 2021 financial statements, as loss exposure was neither probable nor estimable at such times. In 2019, a former customer filed a lawsuit alleging damages associated with defective product. Mediation of the matter was held in November 2022. The Company agreed to make a payment of $2.0 million to settle the matter, and such amount has been reflected in the Selling, General and Administrative line in the three and nine month periods ended October 1, 2022. The Company expects to be indemnified by other parties for approximately $1.5 million and will record the gain as an offset to Selling, General and Administrative expense when received, likely in the fourth quarter of 2022. Other than these proceedings, we are not party to any significant pending legal proceedings that management believes will result in a material adverse effect on our financial condition or results of operations.

Segment Information

Segment Information	9 Months Ended
	Oct. 01, 2022
Segment Reporting [Abstract]
Segment Information	Segment Information Below are the sales and operating loss by segment for the three and nine months ended October 1, 2022 and October 2, 2021 and a reconciliation of segment operating loss to loss before income taxes. Operating loss is net sales less cost of products sold and other operating expenses excluding interest and corporate expenses. Cost of products sold and other operating expenses are directly identifiable to the respective segment. Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Sales: Aerospace $ 322,871 $ 266,425 $ 112,177 $ 95,775 Less Inter-segment Sales (10) (23) — (9) Total Aerospace Sales 322,861 266,402 112,177 95,766 Test Systems 53,899 62,811 19,261 16,128 Less Inter-segment Sales (19) (357) — (53) Total Test Systems Sales 53,880 62,454 19,261 16,075 Total Consolidated Sales $ 376,741 $ 328,856 $ 131,438 $ 111,841 Segment Measure of Operating Loss and Margins Aerospace $ (7,085) $ (6,352) $ (6,859) $ 1,917 (2.2) % (2.4) % (6.1) % 2.0 % Test Systems (4,125) (1,958) (2,312) (2,201) (7.7) % (3.1) % (12.0) % (13.7) % Total Segment Measure of Operating Loss (11,210) (8,310) (9,171) (284) (3.0) % (2.5) % (7.0) % (0.3) % Deductions from Segment Measure of Operating Loss Net Gain on Sale of Business (11,284) — — — Interest Expense, Net of Interest Income 5,812 5,252 2,519 1,795 Corporate Expenses and Other 16,847 13,247 5,570 4,760 Loss Before Income Taxes $ (22,585) $ (26,809) $ (17,260) $ (6,839) During the three and nine months ended October 1, 2022, the Company settled a customer accommodation dispute for $2.1 million and a litigation for $2.0 million, both recorded within Selling, General and Administrative expense and impacting Aerospace segment profitability. Total Assets: (In thousands) October 1, 2022 December 31, 2021 Aerospace $ 478,385 $ 458,334 Test Systems 108,473 105,335 Corporate 12,029 45,469 Total Assets $ 598,887 $ 609,138

Fair Value

Fair Value	9 Months Ended
	Oct. 01, 2022
Fair Value Disclosures [Abstract]
Fair Value	Fair Value A fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is based upon an exit price model. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and involves consideration of factors specific to the asset or liability. The Company follows a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. On a Recurring Basis: A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. On October 4, 2019, the Company acquired the stock of the primary operating subsidiaries as well as certain other assets from mass transit and defense market test solution provider, Diagnosys Test Systems Limited for $7.0 million in cash, plus an earn-out estimated at a fair value of $2.5 million at the time of acquisition. The terms of the Diagnosys acquisition allow for a potential earn-out of up to an additional $13.0 million over the three years post-acquisition based on achievement of new order levels of over $72.0 million during that period. The fair value assigned to the earnout was determined using the real options method, which requires Level 3 inputs such as new order forecasts, discount rate, volatility factors, and other market variables to assess the probability of Diagnosys achieving certain order levels over the period. Based on actual and forecasted new orders, the fair value was zero as of October 1, 2022 and December 31, 2021. The fair value was reduced to zero during the second quarter of 2021, with the contingent consideration liability fair value adjustment of $2.2 million recorded within the Selling, General and Administrative line in the Consolidated Condensed Statement of Operations in the nine months ended October 2, 2021. There were no other financial assets or liabilities carried at fair value measured on a recurring basis at October 1, 2022 or December 31, 2021. On a Non-recurring Basis: There were no non-recurring fair value measurements performed in the nine months ended October 1, 2022 and October 2, 2021.

Restructuring Charges

Restructuring Charges	9 Months Ended
	Oct. 01, 2022
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Charges The COVID-19 pandemic has significantly impacted the global economy, and particularly the aerospace industry, resulting in reduced expectations of the Company’s anticipated future operating results. As a result, the Company executed restructuring activities in the form of workforce reduction, primarily in the second quarter of 2020, to align capacity with expected demand. Additional restructuring activities occurred during 2021 to align the workforce to expected activities and to consolidate certain facilities. Restructuring-related severance charges and other charges were insignificant in the three and nine months ended October 1, 2022. There were $0.5 million and $0.7 million in restructuring-related non-severance charges recorded in the three and nine months ended October 2, 2021. The following table reconciles the beginning and ending liability for restructuring charges: (In thousands) 2022 Balance as of January 1 $ 2,400 Restructuring Charges 199 Cash Paid (2,554) Balance as of October 1 $ 45 The liability is recorded within Accrued Expenses and Other Current Liabilities and is comprised of employee termination benefits expected to be paid within the next 12 months. The cash paid in the nine months ended October 1, 2022 primarily consists of severance payments of $0.4 million and payments under non-cancelable purchase commitments for inventory which was not expected to be purchased prior to the expiration date of such agreements as a result of the restructuring plan of $2.1 million.

Subsequent Events

Subsequent Events	9 Months Ended
	Oct. 01, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsOn October 21, 2022 and November 14, 2022, the Company executed amendments to its Fifth Amended and Restated Credit Agreement. For more information, see Note 7, Debt.

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Oct. 01, 2022
Accounting Policies [Abstract]
Basis of Presentation and Description of the Business	Basis of PresentationThe accompanying unaudited statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial information. Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included. Description of the Business Astronics Corporation (“Astronics” or the “Company”) is a leading provider of advanced technologies to the global aerospace, defense and electronics industries. Our products and services include advanced, high-performance electrical power generation, distribution and motion systems, lighting and safety systems, avionics products, systems and certification, aircraft structures and automated test systems. We have principal operations in the United States (“U.S.”), Canada, France and England, as well as engineering offices in the Ukraine and India.
Operating Results	Operating Results The results of operations for any interim period are not necessarily indicative of results for the full year. In addition, the COVID-19 pandemic and supply chain disruptions have increased the volatility we experience in our financial results in recent periods and this could continue in future interim and annual periods. Operating results for the nine months ended October 1, 2022 are not necessarily indicative of the results that may be expected for the year ending December 31, 2022. The balance sheet at December 31, 2021 has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by U.S. generally accepted accounting principles (“GAAP”) for complete financial statements.
Trade Accounts Receivable and Contract Assets	Trade Accounts Receivable and Contract AssetsThe allowance for estimated credit losses is based on the Company’s assessment of the collectability of customer accounts. The Company regularly reviews the allowance by considering factors such as the age of the receivable balances, historical experience, credit quality, current economic conditions, and reasonable and supportable forecasts of future economic conditions that may affect a customer’s ability to pay.The Company's exposure to credit losses may increase if its customers are adversely affected by global economic recessions, disruption associated with the current COVID-19 pandemic, industry conditions, or other customer-specific factors. Although the Company has historically not experienced significant credit losses, it is possible that there could be a material adverse impact from potential adjustments of the carrying amount of trade receivables and contract assets as airlines and other aerospace companies’ cash flows are impacted by the COVID-19 pandemic.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred and include salaries, benefits, consulting, material costs and depreciation. Research and development expenses amounted to $12.0 million and $11.3 million for the three months ended and $36.8 million and $31.9 million for the nine months ended October 1, 2022 and October 2, 2021, respectively. These costs are included in cost of products sold.
Goodwill Impairment	Goodwill Impairment The Company tests goodwill at the reporting unit level on an annual basis or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.
Valuation of Long-Lived Assets	Valuation of Long-Lived AssetsLong-lived assets are evaluated for recoverability whenever adverse effects or changes in circumstances indicate that the carrying value may not be recoverable. The recoverability test consists of comparing the undiscounted projected cash flows with the carrying amount. Should the carrying amount exceed undiscounted projected cash flows, an impairment loss would be recognized to the extent the carrying amount exceeds fair value.
Newly Adopted Accounting Pronouncement	Newly Adopted Accounting Pronouncement Recent Accounting Pronouncement Adopted Standard Description Financial Statement Effect or Other Significant Matters ASU No. 2021-08 Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers This amendment requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with Topic 606, Revenue from Contracts with Customers , as if it had originated the contracts. Under the current business combinations guidance, such assets and liabilities are recognized by the acquirer at fair value on the acquisition date. The standard will not impact acquired contract assets or liabilities from business combinations occurring prior to the adoption date. This ASU is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, with early adoption permitted. The impact of adoption on the Company's consolidated financial statements will be prospective only and depend on the magnitude of future business acquisitions. Date of adoption: Q1 2022 We consider the applicability and impact of all ASUs. ASUs not listed above were assessed and determined to be either not applicable, or had or are expected to have minimal impact on our financial statements and related disclosures.
Fair Value	Fair Value A fair value measurement assumes that the transaction to sell an asset or transfer a liability occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for the asset or liability. Fair value is based upon an exit price model. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and involves consideration of factors specific to the asset or liability. The Company follows a valuation hierarchy for disclosure of the inputs to valuation used to measure fair value. This hierarchy prioritizes the inputs into three broad levels as follows: Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on our own assumptions used to measure assets and liabilities at fair value. On a Recurring Basis: A financial asset or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Oct. 01, 2022
Accounting Policies [Abstract]
Schedule of COVID-19 Related Government Assistance	The following table presents the COVID-19 related government assistance, including AMJP, recorded during the three and nine months ended October 1, 2022 and October 2, 2021: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Reduction in Cost of Products Sold $ 6,008 $ 3,185 $ — $ 1,706 Reduction in Selling, General and Administrative Expenses — 190 — 43 Total $ 6,008 $ 3,375 $ — $ 1,749

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Oct. 01, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Contract Assets and Liabilities	The following table presents the beginning and ending balances of contract assets and contract liabilities during the nine months ended October 1, 2022: (In thousands) Contract Assets Contract Liabilities Beginning Balance, January 1, 2022 $ 25,941 $ 28,495 Ending Balance, October 1, 2022 $ 31,263 $ 29,838
Schedule of Disaggregation of Revenue	The following table presents our revenue disaggregated by Market Segments as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Aerospace Segment Commercial Transport $ 211,721 $ 143,550 $ 78,389 $ 57,549 Military 41,336 54,847 12,463 17,064 General Aviation 48,748 41,131 14,751 12,109 Other 21,056 26,874 6,574 9,044 Aerospace Total 322,861 266,402 112,177 95,766 Test Systems Segment Aerospace & Defense 53,880 62,454 19,261 16,075 Test Systems Total 53,880 62,454 19,261 16,075 Total $ 376,741 $ 328,856 $ 131,438 $ 111,841 The following table presents our revenue disaggregated by Product Lines as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Aerospace Segment Electrical Power & Motion $ 132,757 $ 102,742 $ 46,155 $ 38,650 Lighting & Safety 90,339 76,929 29,740 25,461 Avionics 67,453 47,355 24,172 14,491 Systems Certification 6,656 7,937 3,985 6,099 Structures 4,600 4,565 1,551 2,021 Other 21,056 26,874 6,574 9,044 Aerospace Total 322,861 266,402 112,177 95,766 Test Systems 53,880 62,454 19,261 16,075 Total $ 376,741 $ 328,856 $ 131,438 $ 111,841

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 01, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consisted of the following: ( In thousands ) October 1, 2022 December 31, 2021 Finished Goods $ 32,484 $ 28,579 Work in Progress 33,867 22,954 Raw Material 123,847 106,043 $ 190,198 $ 157,576

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Oct. 01, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, Plant and Equipment consisted of the following: (In thousands) October 1, 2022 December 31, 2021 Land $ 8,501 $ 8,632 Buildings and Improvements 69,986 70,566 Machinery and Equipment 122,337 121,960 Construction in Progress 8,384 5,680 209,208 206,838 Less Accumulated Depreciation 118,568 111,602 $ 90,640 $ 95,236

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Oct. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Acquired Intangible Assets	The following table summarizes acquired intangible assets as follows: October 1, 2022 December 31, 2021 (In thousands) Weighted Average Life Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Patents 11 years $ 2,146 $ 2,044 $ 2,146 $ 1,979 Non-compete Agreement 4 years 11,082 10,972 11,082 10,592 Trade Names 10 years 11,339 9,151 11,447 8,518 Completed and Unpatented Technology 9 years 47,747 33,784 47,932 30,441 Customer Relationships 15 years 141,939 75,488 142,276 69,033 Total Intangible Assets 12 years $ 214,253 $ 131,439 $ 214,883 $ 120,563
Schedule of Amortization Expense for Acquired Intangibles	All acquired intangible assets other than goodwill and one trade name are being amortized. Amortization expense for acquired intangibles is summarized as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Amortization Expense $ 11,254 $ 11,565 $ 3,728 $ 3,853
Schedule of Amortization Expense for Intangible Assets for Each of Next Five Years	Amortization expense for acquired intangible assets expected for 2022 and for each of the next five years is summarized as follows: (In thousands) 2022 $ 14,922 2023 $ 13,878 2024 $ 12,856 2025 $ 10,935 2026 $ 9,533 2027 $ 7,825

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Oct. 01, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Changes in Carrying Amount of Goodwill	The following table summarizes the changes in the carrying amount of goodwill for the nine months ended October 1, 2022: (In thousands) December 31, 2021 Foreign Currency Translation October 1, 2022 Aerospace $ 36,648 $ (140) $ 36,508 Test Systems 21,634 1 21,635 $ 58,282 $ (139) $ 58,143

Product Warranties (Tables)

Product Warranties (Tables)	9 Months Ended
	Oct. 01, 2022
Guarantees [Abstract]
Schedule of Activity in Warranty Accrual	The Company determines warranty reserves needed by product line based on experience and current facts and circumstances. Activity in the warranty accrual is summarized as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Balance at Beginning of Period $ 8,183 $ 7,018 $ 7,759 $ 6,835 Warranties Issued 2,541 3,506 858 1,485 Warranties Settled (2,769) (2,427) (859) (764) Reassessed Warranty Exposure (221) (808) (24) (267) Balance at End of Period $ 7,734 $ 7,289 $ 7,734 $ 7,289

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Oct. 01, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	Basic and diluted weighted-average shares outstanding are as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Weighted Average Shares - Basic 32,085 30,927 32,241 30,954 Net Effect of Dilutive Stock Options — — — — Weighted Average Shares - Diluted 32,085 30,927 32,241 30,954

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Oct. 01, 2022
Equity [Abstract]
Schedule of Comprehensive Loss and Accumulated Other Comprehensive Loss	The components of accumulated other comprehensive loss are as follows: (In thousands) October 1, 2022 December 31, 2021 Foreign Currency Translation Adjustments $ (8,648) $ (5,407) Retirement Liability Adjustment – Before Tax (10,324) (11,370) Tax Benefit of Retirement Liability Adjustment 2,282 2,282 Retirement Liability Adjustment – After Tax (8,042) (9,088) Accumulated Other Comprehensive Loss $ (16,690) $ (14,495)
Schedule of Other Comprehensive (Loss) Income	The components of other comprehensive (loss) income are as follows: Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Foreign Currency Translation Adjustments $ (3,241) $ (1,165) $ (1,674) $ (1,143) Retirement Liability Adjustments: Reclassifications to General and Administrative Expense: Amortization of Prior Service Cost 302 302 101 101 Amortization of Net Actuarial Losses 744 1,000 247 333 Retirement Liability Adjustment 1,046 1,302 348 434 Other Comprehensive (Loss) Income $ (2,195) $ 137 $ (1,326) $ (709)

Supplemental Retirement Plan _2

Supplemental Retirement Plan and Related Post Retirement Benefits (Tables)	9 Months Ended
	Oct. 01, 2022
Retirement Benefits [Abstract]
Schedule of the Components of Net Periodic Cost	The following table sets forth information regarding the net periodic pension cost for the plans. Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Service Cost $ 103 $ 146 $ 34 $ 49 Interest Cost 626 573 209 192 Amortization of Prior Service Cost 290 290 97 97 Amortization of Net Actuarial Losses 712 970 238 324 Net Periodic Cost $ 1,731 $ 1,979 $ 578 $ 662

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Oct. 01, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	Below are the sales and operating loss by segment for the three and nine months ended October 1, 2022 and October 2, 2021 and a reconciliation of segment operating loss to loss before income taxes. Operating loss is net sales less cost of products sold and other operating expenses excluding interest and corporate expenses. Cost of products sold and other operating expenses are directly identifiable to the respective segment. Nine Months Ended Three Months Ended (In thousands) October 1, 2022 October 2, 2021 October 1, 2022 October 2, 2021 Sales: Aerospace $ 322,871 $ 266,425 $ 112,177 $ 95,775 Less Inter-segment Sales (10) (23) — (9) Total Aerospace Sales 322,861 266,402 112,177 95,766 Test Systems 53,899 62,811 19,261 16,128 Less Inter-segment Sales (19) (357) — (53) Total Test Systems Sales 53,880 62,454 19,261 16,075 Total Consolidated Sales $ 376,741 $ 328,856 $ 131,438 $ 111,841 Segment Measure of Operating Loss and Margins Aerospace $ (7,085) $ (6,352) $ (6,859) $ 1,917 (2.2) % (2.4) % (6.1) % 2.0 % Test Systems (4,125) (1,958) (2,312) (2,201) (7.7) % (3.1) % (12.0) % (13.7) % Total Segment Measure of Operating Loss (11,210) (8,310) (9,171) (284) (3.0) % (2.5) % (7.0) % (0.3) % Deductions from Segment Measure of Operating Loss Net Gain on Sale of Business (11,284) — — — Interest Expense, Net of Interest Income 5,812 5,252 2,519 1,795 Corporate Expenses and Other 16,847 13,247 5,570 4,760 Loss Before Income Taxes $ (22,585) $ (26,809) $ (17,260) $ (6,839) During the three and nine months ended October 1, 2022, the Company settled a customer accommodation dispute for $2.1 million and a litigation for $2.0 million, both recorded within Selling, General and Administrative expense and impacting Aerospace segment profitability. Total Assets: (In thousands) October 1, 2022 December 31, 2021 Aerospace $ 478,385 $ 458,334 Test Systems 108,473 105,335 Corporate 12,029 45,469 Total Assets $ 598,887 $ 609,138

Restructuring Charges (Tables)

Restructuring Charges (Tables)	9 Months Ended
	Oct. 01, 2022
Restructuring and Related Activities [Abstract]
Schedule of Liabilities for Restructuring Charges	The following table reconciles the beginning and ending liability for restructuring charges: (In thousands) 2022 Balance as of January 1 $ 2,400 Restructuring Charges 199 Cash Paid (2,554) Balance as of October 1 $ 45

Basis of Presentation - Narrati

Basis of Presentation - Narrative (Details) $ in Millions		1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
	Feb. 13, 2019 element	Mar. 31, 2022 USD ($)	Jan. 31, 2022 USD ($)	Oct. 01, 2022 USD ($)	Apr. 02, 2022 USD ($)	Oct. 02, 2021 USD ($)	Oct. 01, 2022 USD ($)	Oct. 02, 2021 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)
Business Acquisition [Line Items]
Allowance for doubtful accounts				$ 3.4			$ 3.4		$ 3.2
Bad debt expense				0.3			0.4
Research and development expense				12		$ 11.3	36.8	$ 31.9
USDOT | AMPJ Award
Business Acquisition [Line Items]
USDOT grant receivable amount (up to)										$ 14.7
Portion of grant received				$ 2.1	$ 5.2				$ 7.4
Revenue recognized included in contract liability balance							$ 6
Sold | Semiconductor Test Business | Test Systems
Business Acquisition [Line Items]
Number of elements for contingent earnouts | element	2
Earnout proceeds received		$ 11.3	$ 10.7

Basis of Presentation - COVID-1

Basis of Presentation - COVID-19 Related Government Assistance (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
COVID-19 Related Government Assistance [Line Items]
COVID-19 related government assistance amount	$ 0	$ 1,749	$ 6,008	$ 3,375
Reduction in Cost of Products Sold
COVID-19 Related Government Assistance [Line Items]
COVID-19 related government assistance amount	0	1,706	6,008	3,185
Reduction in Selling, General and Administrative Expenses
COVID-19 Related Government Assistance [Line Items]
COVID-19 related government assistance amount	$ 0	$ 43	$ 0	$ 190

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Dec. 31, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation	$ 547.1		$ 547.1
Revenue recognized included in contract liability balance	7.3	$ 6.5	13.3	$ 15.1
Capitalized cost	1.6		1.6		$ 0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-10-02
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation	$ 426.5		$ 426.5
Period of recognition (in months)	12 months		12 months

Revenue - Summary of Contract A

Revenue - Summary of Contract Assets and Liabilities (Details) - USD ($) $ in Thousands	Oct. 01, 2022	Jan. 01, 2022
Revenue from Contract with Customer [Abstract]
Contract Assets	$ 31,263	$ 25,941
Contract Liabilities	$ 29,838	$ 28,495

Revenue - Revenue Disaggregated

Revenue - Revenue Disaggregated by Market (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Disaggregation of Revenue [Line Items]
Sales	$ 131,438	$ 111,841	$ 376,741	$ 328,856
Aerospace
Disaggregation of Revenue [Line Items]
Sales	112,177	95,766	322,861	266,402
Aerospace | Commercial Transport
Disaggregation of Revenue [Line Items]
Sales	78,389	57,549	211,721	143,550
Aerospace | Military
Disaggregation of Revenue [Line Items]
Sales	12,463	17,064	41,336	54,847
Aerospace | General Aviation
Disaggregation of Revenue [Line Items]
Sales	14,751	12,109	48,748	41,131
Aerospace | Other
Disaggregation of Revenue [Line Items]
Sales	6,574	9,044	21,056	26,874
Test Systems
Disaggregation of Revenue [Line Items]
Sales	19,261	16,075	53,880	62,454
Test Systems | Aerospace & Defense
Disaggregation of Revenue [Line Items]
Sales	$ 19,261	$ 16,075	$ 53,880	$ 62,454

Revenue - Disaggregated by Prod

Revenue - Disaggregated by Product Lines (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Disaggregation of Revenue [Line Items]
Sales	$ 131,438	$ 111,841	$ 376,741	$ 328,856
Aerospace
Disaggregation of Revenue [Line Items]
Sales	112,177	95,766	322,861	266,402
Aerospace | Electrical Power & Motion
Disaggregation of Revenue [Line Items]
Sales	46,155	38,650	132,757	102,742
Aerospace | Lighting & Safety
Disaggregation of Revenue [Line Items]
Sales	29,740	25,461	90,339	76,929
Aerospace | Avionics
Disaggregation of Revenue [Line Items]
Sales	24,172	14,491	67,453	47,355
Aerospace | Systems Certification
Disaggregation of Revenue [Line Items]
Sales	3,985	6,099	6,656	7,937
Aerospace | Structures
Disaggregation of Revenue [Line Items]
Sales	1,551	2,021	4,600	4,565
Aerospace | Other
Disaggregation of Revenue [Line Items]
Sales	6,574	9,044	21,056	26,874
Test Systems
Disaggregation of Revenue [Line Items]
Sales	$ 19,261	$ 16,075	$ 53,880	$ 62,454

Inventories - Summary of Invent

Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished Goods	$ 32,484	$ 28,579
Work in Progress	33,867	22,954
Raw Material	123,847	106,043
Inventory, net	$ 190,198	$ 157,576

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Oct. 01, 2022	Dec. 31, 2021
Property, Plant and Equipment
Property, plant and equipment, gross	$ 209,208	$ 206,838
Less Accumulated Depreciation	118,568	111,602
Property, plant and equipment, net	90,640	95,236
Land
Property, Plant and Equipment
Property, plant and equipment, gross	8,501	8,632
Buildings and Improvements
Property, Plant and Equipment
Property, plant and equipment, gross	69,986	70,566
Machinery and Equipment
Property, Plant and Equipment
Property, plant and equipment, gross	122,337	121,960
Construction in Progress
Property, Plant and Equipment
Property, plant and equipment, gross	$ 8,384	$ 5,680

Intangible Assets - Summary of

Intangible Assets - Summary of Acquired Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Oct. 01, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets
Weighted average life (in years)	12 years
Gross Carrying Amount	$ 214,253	$ 214,883
Accumulated Amortization	$ 131,439	120,563
Patents
Finite-Lived Intangible Assets
Weighted average life (in years)	11 years
Gross Carrying Amount	$ 2,146	2,146
Accumulated Amortization	$ 2,044	1,979
Non-compete Agreement
Finite-Lived Intangible Assets
Weighted average life (in years)	4 years
Gross Carrying Amount	$ 11,082	11,082
Accumulated Amortization	$ 10,972	10,592
Trade Names
Finite-Lived Intangible Assets
Weighted average life (in years)	10 years
Gross Carrying Amount	$ 11,339	11,447
Accumulated Amortization	$ 9,151	8,518
Completed and Unpatented Technology
Finite-Lived Intangible Assets
Weighted average life (in years)	9 years
Gross Carrying Amount	$ 47,747	47,932
Accumulated Amortization	$ 33,784	30,441
Customer Relationships
Finite-Lived Intangible Assets
Weighted average life (in years)	15 years
Gross Carrying Amount	$ 141,939	142,276
Accumulated Amortization	$ 75,488	$ 69,033

Intangible Assets - Summary o_2

Intangible Assets - Summary of Amortization Expense for Acquired Intangibles (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization Expense	$ 3,728	$ 3,853	$ 11,254	$ 11,565

Intangible Assets - Summary o_3

Intangible Assets - Summary of Future Amortization Expense for Intangible Assets (Details) $ in Thousands	Oct. 01, 2022 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2022	$ 14,922
2023	13,878
2024	12,856
2025	10,935
2026	9,533
2027	$ 7,825

Goodwill - Summary of Changes i

Goodwill - Summary of Changes in Carrying Amount of Goodwill (Details) $ in Thousands	9 Months Ended
	Oct. 01, 2022 USD ($)
Goodwill [Roll Forward]
Balance at beginning of period	$ 58,282
Foreign Currency Translation	(139)
Balance at end of period	58,143
Operating Segments | Aerospace
Goodwill [Roll Forward]
Balance at beginning of period	36,648
Foreign Currency Translation	(140)
Balance at end of period	36,508
Operating Segments | Test Systems
Goodwill [Roll Forward]
Balance at beginning of period	21,634
Foreign Currency Translation	1
Balance at end of period	$ 21,635

Long-Term Debt and Notes Paya_2

Long-Term Debt and Notes Payable (Details) - Line of Credit - Fifth Amended Agreement - USD ($)

1 Months Ended

Apr. 01, 2023

Mar. 31, 2023

Jan. 31, 2023

Jan. 17, 2023

Dec. 31, 2022

Oct. 01, 2022

Dec. 31, 2022

Nov. 30, 2022

Dec. 21, 2022

Nov. 21, 2022

Nov. 14, 2022

Oct. 12, 2022

Oct. 11, 2022

Sep. 12, 2022

Aug. 09, 2022

Mar. 01, 2022

Feb. 28, 2022

Revolving Credit Facility

Debt Instrument

Maximum borrowing capacity

$ 180,000,000

$ 180,000,000

$ 190,000,000

$ 225,000,000

$ 375,000,000

Amounts outstanding under revolving line of credit

159,000,000

Remaining capacity under the credit facility

$ 19,900,000

Commitment fee

0.40%

Revolving Credit Facility | Minimum

Debt Instrument

Consent fee basis points

0.05%

Revolving Credit Facility | Maximum

Debt Instrument

Consent fee basis points

0.10%

Revolving Credit Facility | SOFR (at least)

Debt Instrument

Basis spread on variable rate

1%

Revolving Credit Facility | SOFR

Debt Instrument

Basis spread on variable rate

5.50%

Revolving Credit Facility | Subsequent Event

Debt Instrument

Maximum borrowing capacity

$ 170,000,000

$ 170,000,000

$ 180,000,000

$ 180,000,000

Minimum liquidity, unrestricted cash plus unused revolving credit commitments

$ 15,000,000

$ 10,000,000

$ 10,000,000

EBITDA covenant

$ 25,000,000

$ 15,000,000

$ 15,000,000

Revolving Credit Facility | Subsequent Event | SOFR (at least)

Debt Instrument

Basis spread on variable rate

1%

Revolving Credit Facility | Subsequent Event | SOFR

Debt Instrument

Basis spread on variable rate

8.50%

Revolving Credit Facility | Forecast

Debt Instrument

Maximum borrowing capacity

$ 170,000,000

Letter of Credit

Debt Instrument

Maximum borrowing capacity

$ 20,000,000

Amounts outstanding under revolving line of credit

$ 1,100,000

Product Warranties - Narrative

Product Warranties - Narrative (Details)	9 Months Ended
	Oct. 01, 2022
Minimum
Product Warranty Liability
Product warranty period (in months)	12 months
Maximum
Product Warranty Liability
Product warranty period (in months)	60 months

Product Warranties - Summary of

Product Warranties - Summary of Activity in Warranty Accrual (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance at Beginning of Period	$ 7,759	$ 6,835	$ 8,183	$ 7,018
Warranties Issued	858	1,485	2,541	3,506
Warranties Settled	(859)	(764)	(2,769)	(2,427)
Reassessed Warranty Exposure	(24)	(267)	(221)	(808)
Balance at End of Period	$ 7,734	$ 7,289	$ 7,734	$ 7,289

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Income Tax Disclosure [Abstract]
Effective tax rate (as a percent)	13.90%	(4.90%)	(28.30%)	(1.40%)

Earnings Per Share - Earnings P

Earnings Per Share - Earnings Per Share Computations (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Earnings Per Share [Abstract]
Weighted average shares - basic (in shares)	32,241	30,954	32,085	30,927
Net effect of dilutive stock options (in shares)	0	0	0	0
Weighted average shares - diluted (in shares)	32,241	30,954	32,085	30,927
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares included in EPS computation for the equivalent shares needed to fulfill the 401K obligation (in shares)	100
Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common shares excluded from computation (in shares)			1,106	647

Shareholders' Equity - Narrativ

Shareholders' Equity - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Oct. 01, 2022	Oct. 01, 2022
Stockholders Equity
Difference between the cost and the reissuance price		$ 9.2
Treasury Stock
Stockholders Equity
Shares issued to fund 401k obligation (in shares)	124,000	545,000

Shareholders' Equity - Comprehe

Shareholders' Equity - Comprehensive Loss and Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	Oct. 01, 2022	Jul. 02, 2022	Dec. 31, 2021	Oct. 02, 2021	Jul. 03, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' equity	$ 237,088		$ 256,604	$ 251,660
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' equity	(8,648)		(5,407)
Retirement Liability Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' equity	(8,042)		(9,088)
Retirement Liability Adjustment – Before Tax	(10,324)		(11,370)
Tax Benefit of Retirement Liability Adjustment	2,282		2,282
Accumulated Comprehensive Loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders' equity	$ (16,690)	$ (15,364)	$ (14,495)	$ (16,313)	$ (15,604)	$ (16,450)

Shareholders' Equity - Componen

Shareholders' Equity - Components of Other Comprehensive (Loss) Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total Other Comprehensive (Loss) Income	$ (1,326)	$ (709)	$ (2,195)	$ 137
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total Other Comprehensive (Loss) Income	(1,674)	(1,143)	(3,241)	(1,165)
Amortization of Prior Service Cost
Accumulated Other Comprehensive Income (Loss) [Line Items]
Retirement liability adjustments	101	101	302	302
Amortization of Net Actuarial Losses
Accumulated Other Comprehensive Income (Loss) [Line Items]
Retirement liability adjustments	247	333	744	1,000
Retirement Liability Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total Other Comprehensive (Loss) Income	$ 348	$ 434	$ 1,046	$ 1,302

Supplemental Retirement Plan _3

Supplemental Retirement Plan and Related Post Retirement Benefits - Summary of the Components of Net Periodic Cost (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022 USD ($)	Oct. 02, 2021 USD ($)	Oct. 01, 2022 USD ($) retirement_plan	Oct. 02, 2021 USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Number of non-qualified supplemental retirement defined benefit plans | retirement_plan			2
SERP
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service Cost	$ 34	$ 49	$ 103	$ 146
Interest Cost	209	192	626	573
Amortization of Prior Service Cost	97	97	290	290
Amortization of Net Actuarial Losses	238	324	712	970
Net Periodic Cost	$ 578	$ 662	$ 1,731	$ 1,979

Legal Proceedings - Narrative (

Legal Proceedings - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2022	Oct. 01, 2022	Oct. 01, 2022	Dec. 31, 2021
Lufthansa Technik AG
Loss Contingencies [Line Items]
Estimated litigation liability				$ 1,000,000
Damages paid			$ 300,000
Teradyne, Inc. Alleged Patent Infringement
Loss Contingencies [Line Items]
Reserve		$ 0	0	0
Former customer lawsuit
Loss Contingencies [Line Items]
Settlement		2,000,000	2,000,000
Former customer lawsuit | Forecast
Loss Contingencies [Line Items]
Gain recorded	$ 1,500,000
AES | Indirect Sales | Patent Infringement
Loss Contingencies [Line Items]
Reserve		24,100,000	24,100,000	$ 24,600,000
Interest accrued		100,000	500,000
Remaining estimated liability to be paid		$ 700,000	$ 700,000

Segment Information - Summary o

Segment Information - Summary of Segment Reporting Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Dec. 31, 2021
Segment Reporting Information
Sales	$ 131,438	$ 111,841	$ 376,741	$ 328,856
Segment Measure of Operating Loss and Margins
Total operating loss	(14,314)	(4,498)	(26,877)	(19,930)
Deductions from Segment Measure of Operating Loss
Net Gain on Sale of Business	0	0	(11,284)	0
Interest Expense, Net of Interest Income	2,519	1,795	5,812	5,252
Loss Before Income Taxes	(17,260)	(6,839)	(22,585)	(26,809)
Total Assets	598,887		598,887		$ 609,138
Customer Accommodation Dispute
Segment Reporting Information
Litigation settlement, customer accommodation	2,100
Litigation
Segment Reporting Information
Litigation settlement, customer accommodation			2,000
Aerospace
Segment Reporting Information
Sales	112,177	95,766	322,861	266,402
Test Systems
Segment Reporting Information
Sales	19,261	16,075	53,880	62,454
Operating Segments
Segment Measure of Operating Loss and Margins
Total operating loss	$ (9,171)	$ (284)	$ (11,210)	$ (8,310)
Operating margins, percentage	(7.00%)	(0.30%)	(3.00%)	(2.50%)
Operating Segments | Aerospace
Segment Reporting Information
Sales	$ 112,177	$ 95,775	$ 322,871	$ 266,425
Segment Measure of Operating Loss and Margins
Total operating loss	$ (6,859)	$ 1,917	$ (7,085)	$ (6,352)
Operating margins, percentage	(6.10%)	2%	(2.20%)	(2.40%)
Deductions from Segment Measure of Operating Loss
Total Assets	$ 478,385		$ 478,385		458,334
Operating Segments | Test Systems
Segment Reporting Information
Sales	19,261	$ 16,128	53,899	$ 62,811
Segment Measure of Operating Loss and Margins
Total operating loss	$ (2,312)	$ (2,201)	$ (4,125)	$ (1,958)
Operating margins, percentage	(12.00%)	(13.70%)	(7.70%)	(3.10%)
Deductions from Segment Measure of Operating Loss
Total Assets	$ 108,473		$ 108,473		105,335
Less Inter-segment Sales | Aerospace
Segment Reporting Information
Sales	0	$ (9)	(10)	$ (23)
Less Inter-segment Sales | Test Systems
Segment Reporting Information
Sales	0	(53)	(19)	(357)
Corporate Expenses and Other
Deductions from Segment Measure of Operating Loss
Corporate Expenses and Other	5,570	$ 4,760	16,847	$ 13,247
Total Assets	$ 12,029		$ 12,029		$ 45,469

Fair Value (Details)

Fair Value (Details) - USD ($)		9 Months Ended
	Oct. 04, 2019	Oct. 01, 2022	Oct. 02, 2021	Dec. 31, 2021	Jul. 03, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Contingent Consideration Liability Fair Value Adjustment		$ 0	$ 2,200,000
Diagnosys
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash purchase price	$ 7,000,000
Financial liabilities carried at fair value	2,500,000	$ 0		$ 0	$ 0
Potential additional earn-out	$ 13,000,000
Achievement period (in years)	3 years
Earn-out achievement benchmark	$ 72,000,000
Contingent Consideration Liability Fair Value Adjustment			$ 2,200,000

Restructuring Charges - Narrati

Restructuring Charges - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Oct. 01, 2022	Oct. 02, 2021	Oct. 01, 2022	Oct. 02, 2021	Dec. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring, related severance and non-severance charges	$ 0	$ 500	$ 0	$ 700
Non-Cash Severance Expense			0	$ 182
Restructuring reserve	$ 45		45		$ 2,400
Cash Paid			2,554
Severance payments
Restructuring Cost and Reserve [Line Items]
Cash Paid			400
Payments under non-cancelable purchase commitments
Restructuring Cost and Reserve [Line Items]
Cash Paid			$ 2,100

Restructuring Charges - Beginni

Restructuring Charges - Beginning and Ending Liability for Restructuring Charges (Details) $ in Thousands	9 Months Ended
	Oct. 01, 2022 USD ($)
Restructuring Reserve [Roll Forward]
Beginning balance	$ 2,400
Restructuring Charges	199
Cash Paid	(2,554)
Ending balance	$ 45